Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06636383 · ClinicalTrials.gov registry record
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
A clinical trial of Glycogen Storage Disease Type Ia, sponsored by Ultragenyx Pharmaceutical.
- Recruiting
- Registry status
- 140
- Enrollment target
- 19
- Study locations
NCT06636383 is a study of Glycogen Storage Disease Type Ia that is actively recruiting participants, run by Ultragenyx Pharmaceutical. The registered enrollment target is 140 participants, above the 23-participant average among 5 other Glycogen Storage Disease Type Ia trials with a reported enrollment target (509% higher). The trial reports 19 study locations across 14 states.
The verdict
NCT06636383, a study of Glycogen Storage Disease Type Ia, is actively recruiting participants, sponsored by Ultragenyx Pharmaceutical.
- RECRUITING
- Registry status
- 140 participants
- Enrollment target
- 19
- Study locations
Study Summary
The main objective of this observational study is to evaluate the long-term safety and effectiveness of DTX401 for at least 10 years after DTX401 administration.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (19)
Other
- Rigshospitalet - Copenhagen
- Universitätsklinikum Hamburg Eppendorf - Hamburg
- Istituto G Gaslini Ospedale Pediatrico IRCCS - Genoa
- Osaka City General Hospital - Osaka
- Fujita Health University Hospital - Toyoake
- Hospital Clínico Universitario de Santiago - Santiago
California
- Children's Hospital of Orange County - Orange
Colorado
- Children's Hospital Colorado - Denver
Connecticut
- University of Connecticut Health Center - Hartford
Michigan
- University of Michigan - Ann Arbor
North Carolina
- Duke University Medical Center - Durham
Ohio
- The Cleveland Clinic Foundation - Cleveland
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-11-04 |
| Est. Completion | 2036-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06636383
The ClinicalTrials.gov registry entry for NCT06636383 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 23-participant average among 5 other Glycogen Storage Disease Type Ia trials with a reported enrollment target (509% higher). The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glycogen Storage Disease Type Ia appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT06636383 reports 19 study locations spanning 14 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06636383 about?
NCT06636383 is a clinical study titled "Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program". The main objective of this observational study is to evaluate the long-term safety and effectiveness of DTX401 for at least 10 years after DTX401 administration.
What is the current status of trial NCT06636383?
This trial is currently recruiting. The enrollment target is 140 participants. The study started on 2024-11-04. Estimated completion is 2036-12.
What conditions does trial NCT06636383 study?
This clinical trial studies the following conditions: Glycogen Storage Disease Type Ia.
What interventions are being tested in trial NCT06636383?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT06636383?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06636383 being conducted?
This trial has 19 study locations across California, Colorado, Connecticut, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glycogen Storage Disease Type Ia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accuracy of Lactate Meter in GSDIa
RECRUITING
-
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
RECRUITING · Phase 1
-
Accuracy of Home Lactate Meter and Accu-chek Glucometer in Patients With Glycogen Storage Disease
RECRUITING
-
A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)
COMPLETED · Phase 3
-
Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.